Provexis plc(PXS)
GBX --+0.00%
Reward53Moderate
Risk43Moderate
📊75%Data
Thin -69% profit margin · Revenue down 54% YoY
PXS
+0.0 · +0.00%
GBX · LSE
Provexis plc | Healthcare
Profitless Growth
Market Cap:31.08M
ℹ️
Reward Rating
53
Moderate
Bottom 50% (model universe)
75% data coverage
ℹ️
Risk Rating
43
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on PXS to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Provexis plc?

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide.

PXS · Verdict

Moderate reward · moderate risk

PXS stands out on balance sheet and volatility, but watch the cash flow signal.

Based on 88% data coverage

PXS · Verdict

What’s working & what to watch

Strengths 3

  • Balance sheet89/100

    Current ratio 4.08

  • Volatility80/100

    Top decile vs peers

  • Growth72/100

    Rev +49.1% CAGR · earnings +5.5%

Watchouts 2

  • Cash flow12/100

    -26% free-cash-flow margin

  • Profitability15/100

    -35% net margin · -125% ROE

Model-based scoring. For information only — not financial advice.

What is Provexis plc?

Provexis plc, together with its subsidiaries, develops, licenses, and sells functional foods, medical foods, and dietary supplements worldwide. The company offers syrup and powder versions of Fruitflow, a tomato extract that reduces the propensity for aberrant blood clotting typically associated with cardiovascular diseases, such as heart attack and stroke used in various foods, beverages, and dietary supplement formats. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 31.08M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (53)

The scoring profile indicates limited reward potential at this time, with growth and valuation offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap31.08M
P/E RatioN/A
Dividend YieldN/A
52 Week High1.55
52 Week Low0.4
Last AnnualMarch
IPO DateN/A
IncorporatedUK
Shares Outstanding2B
No. of Employees2
IndustryDrug Manufacturers - Specialty & Generic
ExchangeLSE
Beta0.539
CurrencyGBX · Reports in GBP